Cargando…
Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
INTRODUCTION: Pasireotide (PAS) is a novel somatostatin receptor ligands (SRL), used in controlling hormonal hypersecretion in both acromegaly and Cushing’s Disease (CD). In previous studies and meta-analysis, first-generation SRLs were reported to be able to induce significant tumor shrinkage only...
Autores principales: | Mondin, Alessandro, Manara, Renzo, Voltan, Giacomo, Tizianel, Irene, Denaro, Luca, Ferrari, Marco, Barbot, Mattia, Scaroni, Carla, Ceccato, Filippo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283714/ https://www.ncbi.nlm.nih.gov/pubmed/35846311 http://dx.doi.org/10.3389/fendo.2022.935759 |
Ejemplares similares
-
Complications and mortality of Cushing’s disease: report on data collected over a 20-year period at a referral centre
por: Mondin, Alessandro, et al.
Publicado: (2023) -
Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients
por: Ceccato, Filippo, et al.
Publicado: (2021) -
The Methylation Analysis of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Locus in GH-Secreting Pituitary Adenomas
por: Dalle Nogare, Mattia, et al.
Publicado: (2023) -
Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas
por: Voltan, Giacomo, et al.
Publicado: (2023) -
Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
por: Barbot, Mattia, et al.
Publicado: (2022)